A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
ACTIVE_NOT_RECRUITING
Status
Conditions
- Chronic Lymphocytic Leukemia
- CLL
Interventions
- DRUG: Sonrotoclax
- DRUG: Zanubrutinib
Sponsor
BeiGene